DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

DexCom NASDAQ: DXCM used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement.

MarketBeat • May 16, 2026

Dexcom Just Made A Lofty Promise To Its Investors — Why Analysts Are Bullish

Dexcom stock popped Friday after the diabetes devices maker projected at least 10% growth each year from now through 2030.

Investors Business Daily • May 15, 2026

Diabetes Tech Player DexCom Lays Out 2030 Growth Vision

DexCom Inc. (NASDAQ:DXCM) introduced new long-term financial targets during its 2026 Investor Day, outlining expectations for sustained revenue growth and stronger profitability through the end of the decade.

Benzinga • May 15, 2026

Here's Why DexCom (DXCM) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • May 15, 2026

Dexcom to appoint two directors, revamp board committee with Elliott

Medical device maker DexCom said on Thursday it has agreed with activist ​investor Elliott Investment Management to add ‌two independent directors to the company's board and revamp a key board committee.

Reuters • May 14, 2026

DexCom, Inc. (DXCM) Analyst/Investor Day Transcript

DexCom, Inc. (DXCM) Analyst/Investor Day Transcript

Seeking Alpha • May 15, 2026

Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. “We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosensing platforms,” said Jake Leach, Dexcom's president and CEO. “Today's a.

Business Wire • May 14, 2026

3 Reasons Analysts Love DexCom

While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a crucial component of a broader set of tools to address type 2 diabetes. With about 40 million people in the United States suffering from diabetes, and incidents of type 2 diabetes rising across multiple demographics, this core function of this class of medicines is still just as relevant as it was when these drugs first became available.

MarketBeat • May 5, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • May 5, 2026

Dexcom to Host Investor Day on May 14, 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT). The event will include presentations from Dexcom management highlighting the company's market opportunities, business strategy, innovation efforts, and long-term financial outlook. Links to a live webcast of the event will be available on the Dexcom Investor Relations website at investors.dexcom.c.

Business Wire • May 5, 2026